latest news stock values companies glp-1 obesity cardiometabolic Receptor Agonist Market Size & Analysis, 2026-2033 Glucagon-like Peptide-1 (GLP-1) Agonists Market

This could indicate a bowel obstruction, a rare but documented adverse event with GLP-1 receptor agonists

With structured follow-ups at Set Point Medical Weight Loss Clinic, Watson ensures results are safe, measurable, and long-lasting

Glucagon stimulates the liver to release stored glucose, rapidly increasing blood glucose levels

[DOI] [PMC free article] [PubMed] [Google Scholar] 17.Karakousis N., Kostakopoulos N.A., Georgakopoulou V.E., Pyrgioti E.E., Georgakopoulos P.N., Karakousis N.D., Pyrgioti E., Georgakopoulos P

Slow Hair Growth: The rate of new hair growth may be affected while on GLP-1 inhibitors

When the researchers stratified patients who initiated GLP1-RA treatment for obesity (59%) compared with diabetes (41%), they found no improvement in BMI Z-score or weight